

Researcher / Project Manager position at Ninevah Therapeutics



What is Ninevah Therapeutics

[Ninevah Therapeutics](#) is a young biotech developing gene therapies to cure rare monogenic kidney diseases. At Ninevah we work with experts in the fields of kidney biology and gene therapy and we have a global network of excellent researchers and physicians.

The company was founded in Barcelona Q2-2019 and operates from PCB and the Vall d'Hebron Institute of Research (VHIR) where it currently conducts its research. We are also supported by EiT Health HeadStart acceleration program (2020 edition).

What we offer:

- Apply together to a [TecnioSpring](#) contract for a 2-years position at our company (starting date March 2021).
- Possibility of participating in the early development of a therapy that can have a strong impact on society.
- A stimulating environment with the possibility of continuous learning from recognized experts in the field.
- Involvement in technology transfer and management activities related to the project.
- An excellent opportunity to transition from academia to the biotech industry.

What we look for:

- PhD in Molecular biology or related field.
- Certification of mouse handling for laboratory use.
- Experience with molecular biology techniques
- Experience with mouse models.
- Experience in primary cell cultures.
- Lab and project management skills.
- Entrepreneurial spirit.
- Excellent interpersonal skills, initiative and ability to work independently.
- Fluency in spoken and written English.

Recommended but not required:

- Experience with gene therapy.
- Experience in biotech industry.

Project description:

There are at least 150 different rare monogenic kidney disorders for which the only therapeutic option is a kidney transplant. Kidney transplantation is a solution, but it is not a cure since it substantially decreases the quality of life of patients and is expensive for health systems.

At Ninevah Therapeutics we work to cure genetic kidney diseases through the discovery and development of novel and kidney-specific gene therapies. Our leading program is an AAV-based approach for podocyte-associated genetic disorders. We are also building a second discovery program based on a nanoparticle and a gene editing CRISPR approach.

The selected researcher will be responsible for all the laboratory work of the second discovery program. The main task of the researcher will be to validate the technology in a relevant setting, first in vitro and then in vivo, using relevant cellular and mouse models. He/she will also be involved in the management and tech transfer activities of the project.

If you are interested please send your CV and a brief motivation letter to:

gonzalo.fernandez@ninevahtx.com